The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...

Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO ...

Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE ... Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we ...

M.D., '63 director of the Program on Global Public Health and the Common Good and the Boston College Global Observatory on Planetary Health, is the lead author of a groundbreaking new report about the ...

Boston College has established the Global Observatory on Pollution ... “The University’s strategic goals ask us to draw upon our world-class faculty and scientific research to make an impact in the ...